デフォルト表紙
市場調査レポート
商品コード
1218722

ライフサイエンスツールの世界市場

Life Science Tools

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 849 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
ライフサイエンスツールの世界市場
出版日: 2023年01月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 849 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

ライフサイエンスツールの世界市場は2030年に2,586億米ドルへ

変化したCOVID-19後のビジネス環境において、2022年に1330億米ドルと推定されるライフサイエンスツールの世界市場は、2030年までに2586億米ドルの改定規模に達し、分析期間2022-2030年に8.7%のCAGRで成長すると予測されます。本レポートで分析したセグメントの1つである細胞生物学は、CAGR7.8%を記録し、分析期間終了時には826億米ドルに達すると予測されます。パンデミック後の回復を考慮し、ゲノミクス分野の成長は、今後8年間のCAGRが8.9%に修正される見込みです。

米国市場は484億米ドル、中国はCAGR13%の成長予測

米国のライフサイエンスツール市場は、2022年に484億米ドルと推定されます。世界第2位の経済大国である中国は、2022年から2030年にかけてCAGR13%で推移し、2030年までに311億米ドルの市場規模に達すると予測されています。その他の注目すべき地域市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ6.3%と8.2%の成長が予測されています。欧州では、ドイツがCAGR7.5%で成長すると予測されています。

調査対象企業の例

  • Abbott Laboratories Inc.
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bruker Corporation
  • Carl Zeiss AG
  • Eppendorf SE
  • F. Hoffmann-La Roche AG
  • Hitachi High-Tech Corporation
  • Illumina, Inc.
  • Merck KGaA
  • Oxford Instruments plc
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • Shimadzu Corporation
  • Thermo Fisher Scientific Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • 中東
  • アフリカ

第4章 競合

目次
Product Code: MCP22151

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Life Science Tools Market to Reach $258.6 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Life Science Tools estimated at US$133 Billion in the year 2022, is projected to reach a revised size of US$258.6 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2022-2030. Cell Biology, one of the segments analyzed in the report, is projected to record a 7.8% CAGR and reach US$82.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Genomics segment is readjusted to a revised 8.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $48.4 Billion, While China is Forecast to Grow at 13% CAGR

The Life Science Tools market in the U.S. is estimated at US$48.4 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$31.1 Billion by the year 2030 trailing a CAGR of 13% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.3% and 8.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.

Select Competitors (Total 295 Featured):

  • Abbott Laboratories Inc.
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bruker Corporation
  • Carl Zeiss AG
  • Eppendorf SE
  • F. Hoffmann-La Roche AG
  • Hitachi High-Tech Corporation
  • Illumina, Inc.
  • Merck KGaA
  • Oxford Instruments plc
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • Shimadzu Corporation
  • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • A Prelude to Life Sciences Tools
    • Impact of Covid-19 and Global Economic Update
    • War & Inflation Supersede COVID-19 as Major Downside Risks for the Global Economy in 2023 & Beyond
    • Here's How Inflationary Pressures Affect the Economy
    • Russia-Ukraine War, the Primary Culprit Responsible for the Hardships
    • Stubbornly High Inflation to Single Handedly Drag Down Global Growth
    • Here's What's Causing the Current Spike in Inflation
    • EXHIBIT 1: War-Induced Commodity Price Increases & Broad Based Price Pressures Mark the Return of Global Inflation in 2022 to the Highest Level Seen Since 1996: Global Inflation Rates (In %) for the Years 2019 Through 2024
    • EXHIBIT 2: War, Global Inflation, Cost of Living Crisis, Failed Fiscal Policy Attempts to Restore Price Stability & Contain Downside Risks to Result in Sharper-Than-Expected Slowdown in Global Economic Growth: World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2020, 2021, 2022 and 2023
    • EXHIBIT 3: Recession Triggered by Uncontrolled Inflation or Unemployment, Which is the Greater Evil? Inflation Battling Policy Measures to Slowdown Post Pandemic Recovery in Unemployment Rates: Global Number of Unemployed People (In Million) for Years 2019 Through 2023
    • EXHIBIT 4: Year Unemployed People (In Million) 2017, 2018, 2019, 2020, 2021, 2022 & 2023
    • Life Science Tools Market Gains Precedence during COVID-19 Pandemic
    • Competition
    • Players Pursue Product Launch & Innovation to Stay Relevant in Competitive Life Science Tools Market
    • EXHIBIT 5: Life Science Tools - Global Key Competitors Percentage Market Share in 2023 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 308 Players Worldwide in 2023 (E)
    • Global Market Analysis and Prospects
    • Global Life Science Tools Market Appears Primed for Healthy Growth Ahead
    • Cell Biology Holds Significant Revenue Stake
    • Hospitals Remain Primary End-User Segment
    • North America Maintains Front Rank in Global Life Science Tools Market
    • Asia-Pacific to Exhibit Impressive Growth
    • Salient Drivers Keeping Global Life Science Tools Market in Good Shape
    • Technology Trends in the Life Sciences Domain
    • Connected Devices, IoT Ecosystems to Transform the Life Science Landscape
    • Exponential Intelligence, Quantum Computing and Ambient Technologies to Make Headway
    • Cloud Platforms Ease Data Sharing
    • Life Sciences to Gain with Blockchain Edge
    • AI-enabled Automation to Deliver Tangible Benefits for All
    • Cybersecurity Needs Grow for Life Sciences
    • Intertwined Factors with Major Implications for Life Science Domain & Related Tools
    • Recent Market Activity
    • World Brands
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Trends in Life Science Sector Support Demand
    • Why Diagnostic Testing is Key to Mitigate Impact of Infectious Diseases?
    • 3D Cell Culture Transforms Life Sciences Industry
    • EXHIBIT 6: Global 3D Cell Culture Market in US$ Million: 2020 - 2027
    • Increasing Demand for 3D Cell Culture in Drug Discovery
    • Use of 3D Cell Culture for Regenerative Medicine
    • Proteomics Emerges as an Important Research Tool in Battle against COVID-19
    • Proteomics Profiling to Expedite Drug Discovery
    • Proteomics at the Fore with Latest Advances
    • Mass Spectrometry (MS) Expands Application of Proteomics
    • AI and Machine Learning Address Shortcomings of Traditional Equipment in Effectively Identifying Protein Patterns
    • mRNA Technology Gains Spotlight in Life Sciences
    • Innovations in Instrumentation Expand Functionality and Drive Adoption of PCR
    • Synoptic Review of Quantitative PCR Technical Advancements in the Recent Years
    • EXHIBIT 7: Global qPCR and dPCR Instrumentation Market in US$ Million: 2020-2025
    • Genome Sequencing Experiences Host of Evolutionary Waves
    • Greater Integration of Genomic Technologies in the Development of Novel Diagnostics Tests
    • Next Generation Sequencing Drives the Market Growth
    • R&D Activity Remains Vibrant in NGS
    • The Need for Large-scale NGS Data Analysis Pushes for Cloud-enabled Bioinformatics Services
    • Single-Cell Spatial Biology Technologies Poised to Emerge as an Integral Aspect of Future Labs
    • Rising Application of Whole Genome Sequencing Drives Demand for Faster Secondary Analysis Tools
    • Rapid Growth in Biopharma Industry and Rising Investments in R&D to Boost Market Prospects
    • EXHIBIT 8: Global BioPharmaceuticals Market in US$ Billion: 2020 and 2026
    • Liquid Chromatography Drives Growth in New Application Markets
    • Innovative HPLC Products Inject New Growth
    • Digital Transformation of Life Sciences Sector Improves Efficiency and Productivity
    • EXHIBIT 9: Key Initiators of Digital Transformation in Life Sciences
    • Artificial Intelligence offers Multiple Opportunities
    • Wearable Devices Gains Popularity
    • The Cloud Technology Witnesses Rapid Growth
    • VR and E-pharmacy
    • Smart Quality
    • Growing R&D Spending in Pharma and Biotechnology Sectors Presents Opportunities
    • EXHIBIT 10: Pharmaceutical R&D Spending Worldwide (USD Billion) for 2015-2025
    • Technological Developments and Expanding End-Use Applications to Bolster Growth in Mass Spectrometry
    • EXHIBIT 11: Global Chromatography Market (2022): Percentage Share Breakdown of Value Sales by Chromatography Techniques
    • Miniature Mass Spectroscopy Instruments Get Popular
    • Increase in Healthcare Spending to Propel Demand for Life Science Tools
    • EXHIBIT 12: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • The Rise of Data Analytics in Life Sciences
    • Data Science in Drug R&D
    • Data Sharing Emerges as a Significant Trend to Gain Competitive Advantage
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Life Science Tools Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Life Science Tools by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Life Science Tools by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 4: World 16-Year Perspective for Life Science Tools by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Cell Biology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Cell Biology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 7: World 16-Year Perspective for Cell Biology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Genomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Genomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 10: World 16-Year Perspective for Genomics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Proteomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Proteomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 13: World 16-Year Perspective for Proteomics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Healthcare by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Healthcare by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 19: World 16-Year Perspective for Healthcare by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 22: World 16-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Government & Academics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Government & Academics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 25: World 16-Year Perspective for Government & Academics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Life Science Tools Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • Market Analytics
    • TABLE 29: USA Recent Past, Current & Future Analysis for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Life Science Tools by Technology - Percentage Breakdown of Value Revenues for Cell Biology, Genomics, Proteomics and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Life Science Tools by End-Use - Percentage Breakdown of Value Revenues for Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Life Science Tools by Technology - Percentage Breakdown of Value Revenues for Cell Biology, Genomics, Proteomics and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Life Science Tools by End-Use - Percentage Breakdown of Value Revenues for Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses for the Years 2014, 2023 & 2030
  • JAPAN
    • Life Science Tools Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • Market Analytics
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Life Science Tools by Technology - Percentage Breakdown of Value Revenues for Cell Biology, Genomics, Proteomics and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Life Science Tools by End-Use - Percentage Breakdown of Value Revenues for Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses for the Years 2014, 2023 & 2030
  • CHINA
    • Life Science Tools Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • Market Analytics
    • TABLE 47: China Recent Past, Current & Future Analysis for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: China 16-Year Perspective for Life Science Tools by Technology - Percentage Breakdown of Value Revenues for Cell Biology, Genomics, Proteomics and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: China 16-Year Perspective for Life Science Tools by End-Use - Percentage Breakdown of Value Revenues for Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses for the Years 2014, 2023 & 2030
  • EUROPE
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Life Science Tools by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Life Science Tools by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Life Science Tools by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Life Science Tools by Technology - Percentage Breakdown of Value Revenues for Cell Biology, Genomics, Proteomics and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Life Science Tools by End-Use - Percentage Breakdown of Value Revenues for Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses for the Years 2014, 2023 & 2030
  • FRANCE
    • TABLE 62: France Recent Past, Current & Future Analysis for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: France 16-Year Perspective for Life Science Tools by Technology - Percentage Breakdown of Value Revenues for Cell Biology, Genomics, Proteomics and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: France 16-Year Perspective for Life Science Tools by End-Use - Percentage Breakdown of Value Revenues for Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses for the Years 2014, 2023 & 2030
  • GERMANY
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Life Science Tools by Technology - Percentage Breakdown of Value Revenues for Cell Biology, Genomics, Proteomics and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Life Science Tools by End-Use - Percentage Breakdown of Value Revenues for Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Life Science Tools by Technology - Percentage Breakdown of Value Revenues for Cell Biology, Genomics, Proteomics and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Life Science Tools by End-Use - Percentage Breakdown of Value Revenues for Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • TABLE 80: UK Recent Past, Current & Future Analysis for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Life Science Tools by Technology - Percentage Breakdown of Value Revenues for Cell Biology, Genomics, Proteomics and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Life Science Tools by End-Use - Percentage Breakdown of Value Revenues for Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses for the Years 2014, 2023 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Life Science Tools by Technology - Percentage Breakdown of Value Revenues for Cell Biology, Genomics, Proteomics and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Life Science Tools by End-Use - Percentage Breakdown of Value Revenues for Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses for the Years 2014, 2023 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Life Science Tools by Technology - Percentage Breakdown of Value Revenues for Cell Biology, Genomics, Proteomics and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Life Science Tools by End-Use - Percentage Breakdown of Value Revenues for Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Life Science Tools by Technology - Percentage Breakdown of Value Revenues for Cell Biology, Genomics, Proteomics and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Life Science Tools by End-Use - Percentage Breakdown of Value Revenues for Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Life Science Tools by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Life Science Tools by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Life Science Tools by Geographic Region - Percentage Breakdown of Value Revenues for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Life Science Tools by Technology - Percentage Breakdown of Value Revenues for Cell Biology, Genomics, Proteomics and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Life Science Tools by End-Use - Percentage Breakdown of Value Revenues for Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses for the Years 2014, 2023 & 2030
  • AUSTRALIA
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Life Science Tools by Technology - Percentage Breakdown of Value Revenues for Cell Biology, Genomics, Proteomics and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Life Science Tools by End-Use - Percentage Breakdown of Value Revenues for Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses for the Years 2014, 2023 & 2030
  • INDIA
    • Life Science Tools Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • Market Analytics
    • TABLE 119: India Recent Past, Current & Future Analysis for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 121: India 16-Year Perspective for Life Science Tools by Technology - Percentage Breakdown of Value Revenues for Cell Biology, Genomics, Proteomics and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 124: India 16-Year Perspective for Life Science Tools by End-Use - Percentage Breakdown of Value Revenues for Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses for the Years 2014, 2023 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Life Science Tools by Technology - Percentage Breakdown of Value Revenues for Cell Biology, Genomics, Proteomics and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Life Science Tools by End-Use - Percentage Breakdown of Value Revenues for Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses for the Years 2014, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Life Science Tools by Technology - Percentage Breakdown of Value Revenues for Cell Biology, Genomics, Proteomics and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Life Science Tools by End-Use - Percentage Breakdown of Value Revenues for Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses for the Years 2014, 2023 & 2030
  • LATIN AMERICA
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Life Science Tools by Technology - Percentage Breakdown of Value Revenues for Cell Biology, Genomics, Proteomics and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Life Science Tools by End-Use - Percentage Breakdown of Value Revenues for Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses for the Years 2014, 2023 & 2030
  • MIDDLE EAST
    • TABLE 143: Middle East Recent Past, Current & Future Analysis for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Middle East Historic Review for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 145: Middle East 16-Year Perspective for Life Science Tools by Technology - Percentage Breakdown of Value Revenues for Cell Biology, Genomics, Proteomics and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 146: Middle East Recent Past, Current & Future Analysis for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Middle East Historic Review for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 148: Middle East 16-Year Perspective for Life Science Tools by End-Use - Percentage Breakdown of Value Revenues for Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses for the Years 2014, 2023 & 2030
  • AFRICA
    • TABLE 149: Africa Recent Past, Current & Future Analysis for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 150: Africa Historic Review for Life Science Tools by Technology - Cell Biology, Genomics, Proteomics and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 151: Africa 16-Year Perspective for Life Science Tools by Technology - Percentage Breakdown of Value Revenues for Cell Biology, Genomics, Proteomics and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 152: Africa Recent Past, Current & Future Analysis for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 153: Africa Historic Review for Life Science Tools by End-Use - Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 154: Africa 16-Year Perspective for Life Science Tools by End-Use - Percentage Breakdown of Value Revenues for Healthcare, Biopharmaceutical Companies, Government & Academics and Other End-Uses for the Years 2014, 2023 & 2030

IV. COMPETITION